Q-omics provides the consensus-scored ZNF787 profile across patient tissues and cancer cell-line models. ZNF787 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF787 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZNF787 protein abundance shows 19,550 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where ZNF787 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF787 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF787 survival associations across molecular data types. ZNF787 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF787 RNA expression–survival associations across cancer types. High ZNF787 expression shows unfavorable associations in ACC, KIRP, LIHC, LUAD, LGG and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF787 RNA expression.
This table summarizes ZNF787 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF787. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF787 shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, STAD and BRCA. The KIRC box plot shows higher ZNF787 RNA expression in tumor versus normal tissue (log2 FC = +0.752, t-test p < 0.001).
This table shows molecular features associated with ZNF787 in patient tissues and cancer cell lines. In patient samples, ZNF787 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF787 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
